Academy of Advanced Interdisciplinary Studies, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China; School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China; Department of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, PR China.
State Key Laboratory of Biobased Material and Green Papermaking (LBMP), Qilu University of Technology (Shandong Academy of Sciences), Jinan, PR China.
Eur J Med Chem. 2019 Mar 1;165:323-331. doi: 10.1016/j.ejmech.2019.01.042. Epub 2019 Jan 22.
Herein we report the design and synthesis of twenty-two novel benzofuran-isatin-imine hybrids 7a-v tethered through propylene, butylene, pentylene and hexylene, and for the evaluation of their in vitro anti-tubercular and anti-bacterial activities as well as cytotoxicity. All benzofuran-isatin-imine hybrids exhibited considerable in vitro anti-TB (MIC: <0.016-0.218 μg/mL and 0.062-14.15 μg/mL against drug-sensitive and MDR MTB, respectively) and anti-bacterial (MIC: 0.25-64 μg/mL and 0.06-16 μg/mL against Gram-positive and Gram-negative strains, respectively) activities. All of them also showed acceptable cytotoxicity towards VERO (CC: 8-128 μg/mL). The most active hybrid 7j (MIC: <0.016, 0.062 and 0.16 μg/mL, respectively) was >4.8 and ≥ 48 folds more potent than the first line anti-TB agents RIF and INH against both drug-sensitive MTB HRv and MDR-TB isolates, respectively. Moreover, hybrid 7j also demonstrated promising anti-bacterial activities with MIC values of ≤1 μg/mL against the majority of the tested Gram-negative and Gram-positive pathogens, which was comparable to vancomycin (MIC: 0.5-4 μg/mL) and CPFX (MIC: 0.125-8 μg/mL) against Gram-positive bacteria, but slightly less potent than CPFX (MIC: ≤0.03-0.5 μg/mL) against Gram-negative bacteria. The results indicated that benzofuran-isatin-imine hybrids could act as candidates for the development of anti-TB and anti-bacterial agents.
在此,我们报告了二十个新的苯并呋喃-靛红-亚胺杂合体 7a-v 的设计和合成,它们通过丙烯、丁烯、戊烯和己烯连接,并评估了它们的体外抗结核和抗菌活性以及细胞毒性。所有苯并呋喃-靛红-亚胺杂合体均表现出相当的体外抗结核活性(MIC:<0.016-0.218μg/mL 和 0.062-14.15μg/mL,分别针对敏感型和耐多药结核分枝杆菌)和抗菌活性(MIC:0.25-64μg/mL 和 0.06-16μg/mL,分别针对革兰氏阳性和革兰氏阴性菌株)。它们对 VERO(CC:8-128μg/mL)的细胞毒性也可接受。最活跃的杂合体 7j(MIC:<0.016、0.062 和 0.16μg/mL,分别)对敏感型 MTB HRv 和耐多药结核分枝杆菌分离株的抗结核一线药物 RIF 和 INH 的效力分别高出 4.8 倍和≥48 倍。此外,杂合体 7j 还表现出有希望的抗菌活性,对大多数测试的革兰氏阴性和革兰氏阳性病原体的 MIC 值均≤1μg/mL,与万古霉素(MIC:0.5-4μg/mL)和 CPFX(MIC:0.125-8μg/mL)对革兰氏阳性菌相当,但对革兰氏阴性菌的效力略低于 CPFX(MIC:≤0.03-0.5μg/mL)。结果表明,苯并呋喃-靛红-亚胺杂合体可以作为开发抗结核和抗菌药物的候选物。